Clinical Trial Search

Primary: Absolute Vertebral Body Height Restoration as a Percent (Post-procedure Change From Baseline) — 9.72; 11.77; 8.14; 9.07 percent change — p=0.430

Primary: 6 Month Self-reported Abstinence From Smoking — 50; 52; 45; 75 participants

Primary: Number of Participants With at Least 70% Reduction in ADHD Symptoms as Measured by Change in ADHD Rating Scale From First to Last Visit — 6; 2 participants

Primary: Reduction (log10) in Colony Forming Units — 0.734; -0.06 log 10 Colony Forming Units — p==0.006

Primary: Severity of Nasal Obstruction Symptoms at Baseline and Week 12 as Measured by the Total Clinical Score — 3.89; 1.26 Score on a scale

Primary: Change in Asthma Control Questionnaire (ACQ(5)) Score From Baseline at a Regional Level — -0.58 Units on a scale

Primary: Number of Subjects Seroconverted for Anti-rotavirus Immunoglobulin A — 280; 5 subjects

Primary: Intraocular Pressure (IOP) for a 24-Hour Period at Week 4 — 16.8; 21.1; 23.0 Millimeters of mercury (mmHg)

Primary: Change in Frequency of Urge Urinary Incontinence Episodes at Week 12. — -2.5; -1.8 episodes — p=<0.001

Primary: Mean Intraocular Pressure (IOP) at 10 AM at Week 12 — 15.1; 16.9 Millimeters of mercury (mmHg)

Primary: HYLENEX-facilitated Subcutaneous (SC) Rehydration Success — 43 participants

Primary: The Change in Positive and Negative Syndrome Scale(PANSS)Total Score — -26.8 score on a scale

Primary: Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 — 99.2; -12.7 mm Hg — p=<0.05

Primary: Gadolinium-enhancing (Gd+)Lesion Number Change. — 4.0 Gd+ lesions

Primary: Change From Baseline in Asthma Control Test (ACT) After 24 Weeks of Treatment — 5.2; 4.7 Score on a scale